ZURICH BIOTECH+

+ Synthesis & QC Protocol Library

Solid-phase peptide synthesis fundamentals, analytical techniques, quality control systems, and troubleshooting protocols for research-grade production.

TECHNICAL REFERENCE • ZURICH BIOTECH+ • 2026

Protocols: 5

QC Systems: 3

References: 25

+ Solid-Phase Peptide Synthesis (SPPS)

Solid-phase peptide synthesis, introduced by Merrifield in 1963, remains the dominant methodology for producing research peptides. This chapter covers Fmoc-based chemistry — the standard for modern peptide synthesis — including resin selection, coupling reagents, and step-by-step assembly protocols.

+ Principles of SPPS

In SPPS, the peptide chain is assembled from C-terminus to N-terminus on an insoluble polymeric support (resin). The growing chain remains anchored to the resin throughout synthesis, enabling excess reagents and byproducts to be removed by simple filtration and washing — without the need for intermediate purification steps.[1]

The Fmoc (9-fluorenylmethoxycarbonyl) protecting group strategy, introduced by Carpino and Han in 1970 and adapted for solid-phase use in the late 1970s, employs base-labile N-alpha protection (piperidine deprotection) with acid-labile side-chain protection. This orthogonal protection scheme offers significant advantages over the earlier Boc strategy: elimination of repetitive acidolysis steps, milder reaction conditions compatible with sensitive amino acids (notably tryptophan), and improved crude peptide purity.[2]

> **FMOC VS. BOC STRATEGY**
>
> Fmoc chemistry is preferred for routine synthesis and sequences containing multiple Trp residues due to milder conditions. Boc chemistry may be advantageous for sequences containing acid-sensitive modifications or when preparing protected peptide fragments for convergent synthesis.

+ Resin Selection Guide

The solid support determines the C-terminal functionality of the final peptide and influences swelling properties, loading capacity, and compatibility with specific sequences.

RESIN TYPE	APPLICATION	LINKER CLEAVAGE	C-TERMINUS
Wang	Standard acid cleavage	TFA, 1-2 hours	Free acid
Rink Amide	Amide C-terminus	TFA, 1-2 hours	Primary amide
2-CTC (Trityl)	Acid-sensitive sequences; fragment synthesis	Dilute TFA, 10-30 min	Free acid
PAM	Boc chemistry (minimal cleavage)	HF or TFMSA	Free acid
HMBA	Side-chain anchoring; fragment synthesis	HF or hydrazinolysis	Varies
Sieber	Protected peptide amides	1% TFA / DCM	Amide (protected)

+ Coupling Reagents

Carbodiimide and uronium/guanidinium-based coupling reagents activate the carboxyl group of the incoming amino acid for nucleophilic attack by the N-terminal amine of the resin-bound peptide. Reagent selection impacts coupling efficiency, racemization risk, and cost.

REAGENT	MECHANISM	EFFICIENCY	RACEMIZATION RISK	NOTES
DIC / HOBt	Carbodiimide	Good	Low	Cost-effective; standard for routine couplings
HBTU / HOBt / DIPEA	Uronium	Excellent	Very low	Gold standard for Fmoc SPPS
HATU / HOAt / DIPEA	Uronium	Superior	Minimal	Best for difficult sequences; higher cost
PyBOP / HOBt / DIPEA	Phosphonium	Excellent	Very low	Non-uronic byproducts; good for sterically hindered couplings
COMU / DIPEA	Uronium	Excellent	Very low	Water-soluble byproducts; lower allergy risk
Oxyma Pure / DIC	Ethyl cyanohydroxyiminoacetate	Excellent	Very low	Non-explosive HOBt alternative; cost-effective

COUPLING EFFICIENCY WARNING

HATU produces a small quantity of carcinogenic HCN during activation. Always use in a fume hood with adequate ventilation. Oxyma Pure/DIC is the preferred alternative in production environments seeking to minimize toxic byproduct exposure.

+ Fmoc SPPS Standard Protocol

This protocol describes the stepwise assembly of a peptide by Fmoc-based solid-phase synthesis on a standard automated or manual synthesizer. Adapt reagent volumes and wash cycles to your specific instrumentation.

+ EQUIPMENT & REAGENTS

- **R** **Resin:** Wang or Rink Amide, substitution 0.3-0.7 mmol/g
- **S** **Solvents:** DMF (peptide grade, <0.01% amines), DCM for washes
- **A** **Amino acids:** Fmoc-protected, with standard tBu-based side-chain protection
- **C** **Coupling:** HBTU/HOBt (1:1) or HATU/HOAt (1:1), 3 equiv; DIPEA, 6 equiv
- **D** **Deprotection:** 20% piperidine in DMF (v/v)
- **T** **Cleavage:** TFA/TIS/water (95:2.5:2.5) or appropriate scavenger cocktail

Step-by-Step Assembly

SYNTHESIS CYCLE

1. **Resin Swelling:** Add resin to reaction vessel. Swell in DMF for 30-60 minutes with gentle agitation. Drain.
2. **First Amino Acid Attachment (if required):** For 2-CTC resins, pre-load the C-terminal Fmoc-amino acid using DIPEA in DCM (2 equiv, 30-60 min). For Wang/Rink resins, amino acid is pre-loaded.
3. **Initial Deprotection:** Treat resin with 20% piperidine in DMF. First treatment: 1 x 3 min. Second treatment: 1 x 10 min. This removes the Fmoc group from the resin-bound amino acid.
4. **Wash:** Drain piperidine solution. Wash resin with DMF (6 x 1 min with thorough draining between washes).
5. **Kaiser Test (optional):** Confirm complete deprotection. Yellow = complete; blue = incomplete. If incomplete, repeat steps 3-4.
6. **Coupling:** Dissolve Fmoc-amino acid (3 equiv) and HBTU/HOBt (2.9 equiv) in minimal DMF. Add DIPEA (6 equiv) to activate. Add to resin. Agitate for 45-60 minutes at room temperature.
7. **Wash:** Drain coupling solution. Wash with DMF (6 x 1 min).
8. **Coupling Verification:** Perform Kaiser or chloranil test. Blue (Kaiser) or colorless = complete coupling. Yellow (Kaiser) = incomplete — repeat coupling with fresh reagents.
9. **Cycle Repetition:** Repeat steps 3-8 for each amino acid in the sequence, proceeding from C-terminus to N-terminus.
10. **Final Deprotection:** After the last residue is coupled, perform a final Fmoc deprotection (step 3) to expose the free N-terminus.
11. **Final Wash:** Wash resin with DMF (3 x 1 min), then DCM (3 x 1 min). Dry resin thoroughly under vacuum.

Coupling Efficiency Targets

PARAMETER	TARGET	ACCEPTABLE RANGE
Single coupling yield	>99.5%	>99.0%
Double coupling yield	>99.9%	>99.5%
Resin substitution (final)	0.1-0.3 mmol/g	0.05-0.5 mmol/g
Acylation time (standard)	45-60 min	30-120 min
Deprotection time	3 + 10 min	2 + 5 to 5 + 15 min

+ Difficult Sequence Strategies

Certain peptide sequences resist efficient synthesis due to steric hindrance, backbone aggregation, or secondary structure formation on the resin. This chapter covers identification and mitigation strategies.

+ Why Some Sequences Fail

Peptide chains on the resin can self-associate through hydrogen bonding, forming beta-sheet-type aggregates that sterically shield the N-terminus from coupling reagents. This "chain folding" phenomenon is most common in sequences containing:

- Multiple consecutive hydrophobic residues (Val, Ile, Leu, Phe, Trp)
- Beta-branched amino acids (Val, Ile, Thr) adjacent to each other
- Sequences with inherent secondary structure propensity
- Long chains (>30 residues) where resin proximity effects diminish

PROBLEM SIGNATURE	DIAGNOSTIC INDICATOR	SOLUTION STRATEGY
Incomplete deprotection	Kaiser test remains blue after second piperidine treatment	Increase piperidine concentration to 25-30%; extend treatment time; add DBU (2%) as auxiliary base
Incomplete coupling	Kaiser test yellow after standard coupling	Double coupling; switch to HATU/HOAt; increase temperature to 50C; add coupling additives
Aggregation (beta-sheet)	Multiple coupling failures at same position; resin darkening	Pseudoproline dipeptides; Dmb-glycine; reduced resin substitution; solvent switches
Sequence-dependent deletion	MS shows -1 Da pattern; consistent position	Double coupling at problematic position; capping after single coupling; use HATU
Aspartimide formation	MS shows -18 Da; sequences with Asp-Gly/Ser/Thr	Use Fmoc-Asp(OtBu)-(Dmb)Gly pseudoproline; Hmb backbone protection; avoid base excess

+ Pseudoproline Strategy

Pseudoproline derivatives (oxazolidines derived from Ser or Thr) introduce a proline-like kink into the growing peptide chain, disrupting beta-sheet aggregation. The pseudoproline is incorporated as a dipeptide building block and spontaneously converts to the native Ser or Thr residue during the final TFA cleavage.[3]

> **PSEUDOPROLINE APPLICATION GUIDELINES**
>
> Apply pseudoproline dipeptides when: (1) consecutive hydrophobic stretches exceed 4 residues, (2) beta-branched amino acids are adjacent, (3) synthesis consistently fails at a specific position, or (4) the target

sequence exceeds 30 residues. Insert pseudoproline at Ser or Thr positions within the predicted aggregation zone.

+ Alternative Chemistries

When Fmoc chemistry fails despite all mitigation strategies, consider switching to Boc chemistry or employing specialized approaches:

ALTERNATIVE	WHEN TO CONSIDER	TRADE-OFF
Boc chemistry	Multiple Trp residues; acid-sensitive modifications present	Requires HF cleavage (hazardous); different side-chain protection
Microwave-assisted SPPS	Standard conditions fail; rapid synthesis needed	Requires specialized equipment; temperature optimization needed
Fragment condensation	Very long sequences (>50 aa); convergent strategy preferred	Requires protected fragments; racemization risk at ligation point
Native chemical ligation	Unmodified peptides; recombinant proteins	Requires N-terminal Cys; solution-phase technique
Enzymatic synthesis	Specific sequences; green chemistry requirements	Limited substrate scope; optimization intensive

+ Cleavage & Purification

The cleavage step liberates the completed peptide from the resin and simultaneously removes all side-chain protecting groups. The choice of cleavage cocktail and subsequent purification strategy directly determines final product quality.

+ Cleavage Cocktail Formulations

The standard cleavage reagent is trifluoroacetic acid (TFA), which cleaves the peptide-resin linkage and removes tBu-based side-chain protecting groups. Scavengers are added to trap reactive carbocations generated during deprotection, preventing alkylation of sensitive residues (Trp, Tyr, Met).

COCKTAIL	COMPOSITION	BEST FOR	CLEAVAGE TIME
Standard	TFA/TIS/H2O (95:2.5:2.5)	Most standard peptides	1.5-3 hours
Reagent K	TFA/p-cresol/thioanisole/EDT/H2O (82.5:5:5:2.5)	Peptides with multiple Trp, Cys, Met	2-4 hours
Reagent B	TFA/p-cresol/H2O (88:5:5)	Peptides with Arg(Mtr); minimal for standard use	1-6 hours
Reagent R	TFA/thioanisole/EDT/anisole (90:5:3:2)	Complex, sensitive sequences	2-6 hours
Reagent H	TFA/DMS/TIS/EDT/H2O (86:5:3:2:4)	Heavily protected sequences	1-2 hours

CLEAVAGE SAFETY

TFA is highly corrosive and volatile. All cleavage operations must be performed in a fume hood with appropriate PPE (face shield, acid-resistant gloves, lab coat). Never evaporate TFA on an open bench. Use a rotary evaporator with TFA-compatible seals or nitrogen blow-down in a ventilated enclosure.

+ Step-by-Step Cleavage Protocol

+ CLEAVAGE PROCEDURE

1. **Prepare cocktail:** Mix TFA and scavengers in a clean, dry round-bottom flask in a fume hood. Chill to 0C.
2. **Add resin:** Add dried peptidyl-resin to the chilled cleavage cocktail (10-15 mL per gram of resin). Swirl gently to suspend.
3. **Reaction:** Stir at 0C for the initial 30 minutes, then at room temperature for the remaining time (total 1.5-4 hours depending on cocktail and sequence).
4. **Filtration:** Filter the cleavage mixture to remove resin beads. Wash resin 2x with fresh TFA and combine filtrates.
5. **Precipitation:** Concentrate the filtrate by rotary evaporation (optional). Dropwise add the concentrated solution into 10x volume of cold diethyl ether or methyl tert-butyl ether with rapid stirring.
6. **Collection:** Allow precipitate to settle (30 min at -20C). Centrifuge at 3000 rpm for 5 minutes. Decant ether supernatant carefully.
7. **Wash:** Resuspend crude peptide pellet in fresh cold ether. Centrifuge again. Repeat wash 2x.
8. **Drying:** Dry crude peptide under vacuum (lyophilizer or high-vacuum desiccator) until constant weight achieved and ether odor absent.

+ RP-HPLC Purification

Reverse-phase HPLC is the primary purification method for synthetic peptides, separating the target peptide from truncated sequences, deletion peptides, and side products based on hydrophobicity.[4]

PARAMETER	ANALYTICAL	PREPARATIVE
Column	C18, 4.6 x 250 mm, 5 um	C18, 22 x 250 mm, 10 um
Flow rate	1.0 mL/min	15-25 mL/min
Mobile phase A	0.1% TFA in H2O	0.1% TFA in H2O
Mobile phase B	0.1% TFA in acetonitrile	0.1% TFA in acetonitrile
Gradient	5-95% B over 30 min	Optimized from analytical run
Detection	UV 214 nm, 280 nm	UV 214 nm
Load capacity	10-100 ug	50-200 mg

GRADIENT DEVELOPMENT RULE OF THUMB

> Determine the percentage acetonitrile required to elute the peptide on an analytical column at 1% B/min. For preparative purification, begin the shallow gradient (0.1% B/min) 12% below the analytical elution percentage. This maximizes resolution between the target product and closely eluting impurities.

+ Analytical Characterization

Rigorous analytical characterization confirms identity, purity, and quality of the purified peptide. A minimum analytical package includes HPLC purity assessment and mass spectrometry confirmation.

+ HPLC Purity Assessment

Analytical RP-HPLC verifies that the purified peptide meets the required purity specification. The method should resolve the target peptide from known impurities and degradation products.

Method development considerations: The gradient steepness (percent acetonitrile change per minute) is the primary parameter affecting resolution. Shallower gradients improve separation but increase run time. For purity assessment, a gradient of 0.5-1.0% B per minute over the relevant range is recommended. The TFA concentration should be 0.1% in both mobile phases for consistent ion-pairing behavior.[4]

System suitability criteria: Before analyzing peptide samples, verify column performance with a standard peptide mixture. Resolution between adjacent peaks should be >2.0, and peak symmetry should be 0.9-1.2. A representative chromatogram of the standard should be retained for batch records.

+ Mass Spectrometry Confirmation

Mass spectrometry provides unambiguous confirmation of molecular identity by measuring the exact molecular weight of the peptide. Two ionization techniques dominate peptide analysis:

TECHNIQUE	MASS RANGE	RESOLUTION	BEST APPLICATION
ESI-MS	500-5000 Da (singly charged)	0.01-0.1 Da	General confirmation; multiple charge states enable high-mass analysis
MALDI-TOF	500-50,000 Da	0.1-0.5 Da	Quick screening; intact mass; mixed peptide samples
HRMS (ESI-QTOF/Orbitrap)	Unlimited	<5 ppm	Exact mass confirmation; impurity identification

ACCEPTANCE CRITERIA FOR MS IDENTITY

The observed monoisotopic molecular weight must agree with the theoretical value within instrument tolerance: +/- 1.0 Da for ESI-MS and MALDI-TOF, +/- 0.05 Da (or 5 ppm) for high-resolution instruments. Multiple charge states (ESI) or adduct ions should be consistent with the expected peptide mass.

+ Additional Analytical Techniques

For critical applications, supplementary analyses provide further quality assurance:

TECHNIQUE	INFORMATION PROVIDED	WHEN REQUIRED
Amino Acid Analysis (AAA)	Composition verification; peptide content quantification	Reference standards; formulation work; regulatory submissions
Peptide Sequencing (Edman)	N-terminal sequence confirmation	Very long sequences; uncertain synthesis fidelity
Capillary Electrophoresis (CE)	Purity orthogonal to HPLC; charge heterogeneity	Disputed HPLC purity; impurity characterization
Circular Dichroism (CD)	Secondary structure (alpha-helix, beta-sheet)	Structure-function studies; bioactivity correlation
Dynamic Light Scattering (DLS)	Aggregation state; particle size distribution	Aggregation-prone sequences; formulation development

+ Quality Control Systems

A robust QC system ensures that each peptide batch meets specifications before release for experimental use. This chapter outlines in-process controls, batch release testing, and documentation requirements for research-grade peptide production.

+ In-Process Control (IPC) Checkpoints

CHECKPOINT	METHOD	FREQUENCY	ACCEPTANCE
Deprotection completeness	Kaiser ninhydrin test	Every cycle	Blue = complete (negative for free amines)
Coupling completeness	Kaiser or chloranil test	Every cycle	Yellow (Kaiser) = complete (no free amines)
Resin substitution check	Fmoc UV quantification	After loading; every 5 cycles	Expected loading +/- 10%
Reagent quality	Visual inspection; COA review	Each batch	Within expiry; correct appearance
Environmental monitoring	Temperature, humidity log	Continuous	Temp 18-25C; humidity <60%

+ Batch Release Testing Protocol

+ RELEASE TESTING SEQUENCE

1. **Visual inspection:** White to off-white powder; free-flowing; no visible discoloration or foreign particles.
2. **Identity (MS):** Molecular weight within tolerance of theoretical value. Record observed vs. theoretical mass.
3. **Purity (HPLC):** Area percent purity at or above specification (typically >95% or >98%). Integrate all peaks at 214 nm.
4. **Solubility test:** Dissolves to clear solution in specified solvent at stated concentration within 10 minutes.
5. **Water content:** Karl Fischer or thermogravimetric analysis. Typically <10% for lyophilized peptides.
6. **Endotoxin (optional):** LAL test for in vivo applications. Limit: <0.5 EU/mg for animal research; <0.25 EU/mg for higher-grade applications.
7. **Documentation review:** COA completed; batch record reviewed; deviations documented and approved.

+ Stability Study Design

Stability data supports assigned shelf life and storage conditions. A typical research-grade stability program includes:

CONDITION	TEMPERATURE	TIME POINTS	TESTS
Long-term	-20C (recommended storage)	0, 6, 12, 24, 36 months	Appearance, HPLC purity, MS identity
Accelerated	+25C / 60% RH	0, 3, 6 months	Appearance, HPLC purity, MS identity
Stress (solution)	+25C, +37C, +45C	0, 7, 14, 28 days	HPLC purity, degradation kinetics
Photostability	ICH Q1B conditions	0, 7 days	Appearance, HPLC purity

DOCUMENTATION AND TRACEABILITY

Maintain complete batch records including: raw material lot numbers, resin substitution data, stepwise coupling and deprotection results, cleavage conditions, purification parameters, analytical results, and final packaging records. All records must be signed, dated, and archived for a minimum of 3 years or per institutional requirements.

+ Troubleshooting Guide

Rapid diagnosis of synthesis failures saves time and resources. This chapter provides symptom-based troubleshooting for the most common problems encountered in research-scale peptide synthesis.

SYMPTOM	PROBABLE CAUSE	IMMEDIATE ACTION	PREVENTION
Low crude purity (<50%)	Incomplete couplings; deletion sequences	Review Kaiser tests; double-couple failed positions	Reduce resin substitution; use HATU
Correct mass + 106 Da	Benzylation of Trp/Tyr by cationic resin	Add 5% p-cresol to cleavage cocktail	Use PEG-based resins; minimize acid exposure
Correct mass + 56 Da	tBu adduct on Tyr/Trp/Ser/Thr	Extend cleavage time; use stronger scavenger cocktail	Use appropriate scavenger ratio
Correct mass - 18 Da	Aspartimide formation (Asp-Gly/Ser/Thr)	Use pseudoproline dipeptides; add HOBt to piperidine	Design out Asp-Gly sequences if possible
Correct mass - 2 Da	Methionine oxidation	Reduce with DTT or TCEP; add Met(O)-specific cleavage	Use thioanisole scavenger; oxygen-free atmosphere
Broad HPLC peak	Cis/trans proline isomers; aggregation	Increase column temperature; add denaturant to mobile phase	Proline position optimization
Two close MS peaks	Clipped C-terminal amide; racemization	Verify resin loading; check coupling conditions	Use pre-loaded resins; minimize base excess
Peptide will not dissolve	High hydrophobicity; aggregation	Try 10% acetic acid or 10% DMSO; sonicate briefly	Solubility prediction software; sequence design
Yellow discoloration	Trp alkylation; oxidation	Add scavengers; reduce with DTT	Minimize TFA exposure time; protect from light

+ Decision Flowchart Summary

QUESTION	IF YES	IF NO
Is MS mass correct?	Check purity method; optimize purification	Review synthesis chemistry; check for known side reactions
Is purity >90%?	Proceed to aliquoting and QC release	Identify impurities by MS; optimize synthesis or purification
Are impurities truncated?	Improve coupling efficiency; double-couple	Check for chemical modifications; review cleavage conditions
Will it dissolve?	Proceed with experimental work	Try alternative solvents; consider sequence modification
Is it stable in solution?	Define storage conditions and expiry	Reformulate buffer; add stabilizers; aliquot and freeze

+ Clinical & Technical References

[1] Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. *Journal of the American Chemical Society*. 1963;85(14):2149-2154. doi:10.1021/ja00897a025.

[2] Carpino LA, Han GY. The 9-fluorenylmethoxycarbonyl amino-protecting group. *Journal of Organic Chemistry*. 1972;37(22):3404-3409. doi:10.1021/jo00995a005.

[3] Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. *International Journal of Peptide and Protein Research*. 1990;35(3):161-214. doi:10.1111/j.1399-3011.1990.tb01768.x.

[4] Mant CT, Hodges RS. HPLC analysis and purification of peptides. *Methods in Molecular Biology*. 2020;2141:155-189. doi:10.1007/978-1-0716-0524-2_8. PMCID: PMC7119934.

[5] Chan WC, White PD, eds. *FMOC Solid Phase Peptide Synthesis: A Practical Approach*. Oxford University Press; 2000.

[6] Atherton E, Sheppard RC. *Solid Phase Peptide Synthesis: A Practical Approach*. IRL Press; 1989.

[7] Isidro-Llobet A, Alvarez M, Albericio F. Amino acid-protecting groups. *Chemical Reviews*. 2009;109(6):2455-2504. doi:10.1021/cr800323s.

[8] Benoiton NL. *Chemistry of Peptide Synthesis*. CRC Press; 2006.

[9] Stewart JM, Young JD. *Solid Phase Peptide Synthesis*. 2nd ed. Pierce Chemical Company; 1984.

[10] Sewing A, Hausch F. Synthesis of difficult peptide sequences: comparison of different strategies. *Journal of Peptide Science*. 2017;23(7-8):536-543. doi:10.1002/psc.3014.

[11] Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. *Nature Protocols*. 2007;2(12):3247-3256. doi:10.1038/nprot.2007.458.

[12] Subiros-Funosas R, El-Faham A, Albericio F. Solid-phase synthesis of difficult peptides by using Oxyma/DIC. *Journal of Peptide Science*. 2012;18(12):764-768. doi:10.1002/psc.2451.

[13] Bacsa B, Horváti K, Bősze S, et al. Solid-phase synthesis of difficult peptide sequences at elevated temperatures: a critical comparison of microwave and conventional heating technologies. *Journal of Organic Chemistry*. 2008;73(19):7532-7542. doi:10.1021/jo801184k.

[14] Hnilova M, Oren EE, Seker UOS, et al. Effect of molecular conformations on the adsorption behavior of gold-binding peptides. *Langmuir*. 2008;24(21):12440-12445. doi:10.1021/la802250a.

[15] Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. *Journal of Peptide Science*. 2016;22(1):4-27. doi:10.1002/psc.2836.

[16] Guzman F, Barberis S, Illanes A. Peptide synthesis: chemical or enzymatic. *Electronic Journal of Biotechnology*. 2007;10(2):136-149. doi:10.2225/vol10-issue2-fulltext-3.

[17] Mitchell AR, Kent SBH, Engelhard M, Merrifield RB. A new synthetic route to tert-butyloxycarbonylaminoacyl-4-(oxymethyl)phenylacetamidomethyl-resin, an improved support for solid-phase peptide synthesis. *Journal of Organic Chemistry*. 1978;43(13):2845-2852. doi:10.1021/jo00408a022.

[18] Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. *Analytical Biochemistry*. 1970;34(2):595-598. doi:10.1016/0003-2697(70)90146-6.

[19] Vágner J, Over H, Albericio F. Techniques and applications of cleavage/scavenger systems in solid-phase peptide synthesis. *Journal of Peptide Research*. 2000;55(3):216-223. doi:10.1034/j.1399-3011.2000.00120.x.

[20] Sole NA, Barany G. Optimization of solid-phase synthesis of [Ala8]-dynorphin A. *Journal of Organic Chemistry*. 1992;57(20):5399-5403. doi:10.1021/jo00046a041.

[21] King DS, Fields CG, Fields GB. A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. *International Journal of Peptide and Protein Research*. 1990;36(3):255-266. doi:10.1111/j.1399-3011.1990.tb00969.x.

[22] Schnolzer M, Alewood P, Jones A, Alewood D, Kent SBH. In situ neutralization in Boc-chemistry solid phase peptide synthesis. *International Journal of Peptide and Protein Research*. 2007;40(3-4):180-193. doi:10.1111/j.1399-3011.1992.tb00298.x.

[23] Pearson DA, Blanchette M, Baker ML, Guindon CA. Trialkylsilanes as scavengers for the trifluoroacetic acid deblocking of protecting groups in peptide synthesis. *Tetrahedron Letters*. 1989;30(21):2739-2742. doi:10.1016/S0040-4039(01)80276-5.

[24] Lloyd-Williams P, Albericio F, Giralt E. *Chemical Approaches to the Synthesis of Peptides and Proteins*. CRC Press; 1997.

[25] United States Pharmacopeia. *USP General Chapter <921> Water Determination*. USP-NF 2023; Issue 1.